5636 - V-delta-1 T cells are resident in the human lung and associate with survival in patients with non-small cell lung cancer in the TRACERx Study https://www.abstractsonline.com/pp8/#!/10517/presentation/18670
5710 - Identification of convergent gene repression mechanisms through integrative genomic and DNA methylation analysis in TRACERx https://www.abstractsonline.com/pp8/#!/10517/presentation/18766
5818 - Features of cancer cachexia in non-small cell lung cancer: Insights from the prospective TRACERx study https://www.abstractsonline.com/pp8/#!/10517/presentation/18790
6080 - The heterogeneity and evolution of lung neuroendocrine tumors within TRACERx https://www.abstractsonline.com/pp8/#!/10517/presentation/18959
6091 - Evolutionary characterisation of lung adenocarcinoma pathological subtypes in TRACERx https://www.abstractsonline.com/pp8/#!/10517/presentation/18970
6113 - Spatially resolved biomarker detection on single cells in TRACERx using multiplex imaging https://www.abstractsonline.com/pp8/#!/10517/presentation/18032
6217 - TP53 loss with whole genome doubling mediates heterogeneous intra-patient therapy response in EGFR-driven lung adenocarcinoma: A TRACERx study https://www.abstractsonline.com/pp8/#!/10517/presentation/19053
LB504 - Automated grading of growth patterns in lung adenocarcinoma-from TRACERx to LATTICe-A https://www.abstractsonline.com/pp8/#!/10517/presentation/19990
Lung cancer evolution and its prognostic impact https://www.abstractsonline.com/pp8/#!/10517/presentation/435
692 - Patient-derived co-cultures of TRACERx lung cancer organoids and autologous T-cells reveal heterogeneity in immune evasion between cancer subclones https://www.abstractsonline.com/pp8/#!/10517/presentation/13698
645 - Heterogeneity of immunotherapy biomarkers in the TRACERx non-small cell lung cancer multi-region lung cancer cohort study https://www.abstractsonline.com/pp8/#!/10517/presentation/12564
674 - Tracking the transcriptome of lung cancer-associated fibroblasts within the TRACERx lung study from patient to culture models reveals phenotypic plasticity and instructive cues from cancer cells https://www.abstractsonline.com/pp8/#!/10517/presentation/13235
1211 / 7 - Allele-specific copy-number based deconvolution of bulk tumour RNA sequencing data from the TRACERx study https://www.abstractsonline.com/pp8/#!/10517/presentation/15832
1394 / 25 - Pervasive allele specific transcriptional repression of the class I and II HLA genes in TRACERx non-small cell lung cancer https://www.abstractsonline.com/pp8/#!/10517/presentation/14639
1591 / 6 - Convergence of antigenic diversity and Tex-cell stability fatally constrains immune surveillance in non-small cell lung cancer (TRACERx) and HIV-1 infection (Protocol C) https://www.abstractsonline.com/pp8/#!/10517/presentation/14124
1603 / 18 - Genomic transcriptomic evolution in TRACERx lung cancer and metastasis https://www.abstractsonline.com/pp8/#!/10517/presentation/14137
1699 / 16 - SignaTree: A tool to identify evolutionary trajectories of the activity of mutational processes in TRACERx https://www.abstractsonline.com/pp8/#!/10517/presentation/14141
1926 / 5 - Machine learning-enhanced image and spatial analytic pipelines for imaging mass cytometry applied to the TRACERx non-small cell lung cancer study https://www.abstractsonline.com/pp8/#!/10517/presentation/14797
2197 - Targeted cancer therapy induces APOBEC fueling the evolution of drug resistance https://www.abstractsonline.com/pp8/#!/10517/presentation/13694
2144 - Holistic sampling of clonal dynamics using cfDNA in lung TRACERx https://www.abstractsonline.com/pp8/#!/10517/presentation/12566
2784 / 18 - A robust copy number based clonality classification for multiple pulmonary tumors in routine pathology practice by shallow next generation sequencing of formalin fixed clinical specimens https://www.abstractsonline.com/pp8/#!/10517/presentation/12713
3043 / 1 - Exploring the microbial landscape of NSCLC through TRACERx https://www.abstractsonline.com/pp8/#!/10517/presentation/11523
3096 / 3 - Multi-region patient-derived xenograft models from non-small cell lung cancer patients enrolled in lung TRACERx https://www.abstractsonline.com/pp8/#!/10517/presentation/14356
LB153 / 6 - Clinical relevance of spatial intermixing of growth patterns and immune infiltration in lung adenocarcinoma-from TRACERx to LATTICe-A https://www.abstractsonline.com/pp8/#!/10517/presentation/20375
3626 - Genomic evolutionary patterns in matched pre-invasive and invasive lung disease in TRACERx https://www.abstractsonline.com/pp8/#!/10517/presentation/16334
3609 - Defining extrinsic and intrinsic mechanisms of immune evasion in TRACERx using imaging mass cytometry https://www.abstractsonline.com/pp8/#!/10517/presentation/13896
3792 / 5 - TRACERx: Mapping the evolution of metastases in non-small cell lung cancer https://www.abstractsonline.com/pp8/#!/10517/presentation/14147
Recent ACHL News
- Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 04/04/2024 10:45:00 AM
- Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning • GlobeNewswire Inc. • 04/04/2024 10:30:00 AM
- Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference • GlobeNewswire Inc. • 02/05/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 06:14:13 PM
- Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction • GlobeNewswire Inc. • 12/18/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 09:36:37 PM
- Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 11/13/2023 09:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/01/2023 09:26:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/22/2023 08:42:59 PM
- Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement • GlobeNewswire Inc. • 09/22/2023 08:30:00 PM
- Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation • InvestorsHub NewsWire • 09/20/2023 12:45:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/17/2023 07:16:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/04/2023 11:42:07 AM
- Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 08/04/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/29/2023 08:03:49 PM
- Achilles Therapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 06/12/2023 12:00:00 PM
- Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights • GlobeNewswire Inc. • 05/10/2023 11:15:00 AM
- Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens • GlobeNewswire Inc. • 05/10/2023 11:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM